Close Menu
Pushed along by 30-percent growth in life sciences receipts, Agilent last week said overall revenues rose 8.9 percent for its fiscal fourth quarter.
During the quarter ended Oct. 31, the company posted overall revenues of $1.45 billion, up from $1.33 billion a year ago. The climb came almost exclusively from Agilent’s Bio-Analytical Measurement division, which houses the company’s proteomics tools. During the quarter receipts in the division increased 24 percent to $558 million from $450 million a year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.